-
PROVIDERS
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
LIFE SCIENCES
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
Original Webinar Date:
04/12/2024
Liquid biopsy’s role in biomarker-driven NSCLC Management
Discover how Dr. Wade Iams of Vanderbilt University is utilizing liquid biopsy as a valuable tool for broad biomarker detection and monitoring resistance mechanisms to therapeutic pressure in NSCLC.
Speakers
Wade Iams, MD
Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center
Gary I. Grad, MD
Senior Medical Oncologist, Tempus
Ezra Cohen, MD FRCPSC, FASCO
Chief Medical Officer of Oncology, Tempus
Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center
Gary I. Grad, MD
Senior Medical Oncologist, Tempus
Ezra Cohen, MD FRCPSC, FASCO
Chief Medical Officer of Oncology, Tempus
-
06/25/2024Revolutionizing Cardiac Care: AI-driven detection and treatment of critical heart valve disease at Boulder Community Health
Discover how Tempus Next's AI-powered care pathway platform transformed patient outcomes by helping ensure timely, guideline-directed treatment for critical heart valve disease at Boulder Community Health
Read more -
04/15/2024Identifying patients with Valvular Heart Disease: A partnership between St.Francis and Tempus
Learn how the deployment of Tempus Next, an AI-enabled clinical care pathway solution at St. Francis enabled guideline directed care for patients with structural heart disease.
Read more -
04/15/2024Closing the biomarker testing gap for early stage NSCLC patients with Tempus Next
Learn how Tempus Next was deployed at TriHealth Cancer and Blood Institute in Cincinnati, Ohio to surface and close gaps in biomarker testing for NSCLC patients.
Read more